Document:

Exhibit 10.2

 

 

MASTER
SERVICES AGREEMENT

By and
Between

 

TME
RESEARCH

And

The
National Reference Laboratory for Breast Health, Inc.

 

This Master
Services Agreement (“Agreement”)
is effective as of September 1, 2014
and is by and between TME Research LLC (“TME
RESEARCH”), with a principal place of business at 250
Cetronia Road, Suite 302,
Allentown, PA 18104, and
The National Reference Laboratory for Breast Health, Inc. (“COMPANY”), with a principal place of business at 1616
Eastlake Ave. East, Suite 360, Seattle,
WA 98102.

 

WHEREAS,
TME RESEARCH is engaged in the business of providing Breast Cancer Study and Research Services such as access to tissue
and patient registries, study concept and design; IRB interface services, on-line database development, study implementation including
study set-up, launch, investigator recruitment, and oversight, data monitoring; and associated work including but not limited to
data analysis, summary, and preparation for publication and/ or public release, as well as access to the TME Scientific Advisory
Board; and

 

WHEREAS,
COMPANY is in the business of developing innovative breast health products and services designed to provide critical
information that empowers women and their healthcare providers to take charge of and protect their breast health today and in the
future and;

 

Whereas
COMPANY desires to acquire and analyze matched sets of patient tissue with clinically annotated data with its NextCYTE microarray
test and

 

Whereas
TME RESEARCH desires to provide such specific services to COMPANY as specifically defined in an attachment to this Agreement and
under the restrictions set out in agreed upon terms and conditions;

 

Now
therefore, for and in consideration of the mutual promises contained herein, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the parties agree as set forth herein.

 

1.          DEFINITIONS

 

1.1        "TME
RESEARCH Data” means any TME RESEARCH data and information provided to COMPANY by
TME RESEARCH for use under this Agreement or applicable Statement(s) of Work, including all patient electronic medical data of
which such data shall be de-identified and provided in accordance with Data Specifications set forth in this Agreement. For the
purpose of this Agreement, TME RESEARCH Data shall not include any patient tissue samples or the like provided by TME Research
to COMPANY. For the purpose of this Agreement, TME RESEARCH Data shall not include any data subject to any applicable law, legal,
contractual, or other restriction against such provision of data by any source of such data.

 

1.2        “Applicable
Law” means any international, national, federal, state, provincial, commonwealth,
or local government law, statute, rule, requirement, code, regulation, or ordinance that applies to either party or to the services
or this Agreement, and includes without limitation, rules of HIPAA.

 

	Page 1 of 8	Confidential
	TME Research July 2014 Vers.02cf	 

 

    	 

    	 

    

 

1.3           “Confidential
Information” means information inthe possession or under control of either TME
RESEARCH or COMPANY including without limitation the terms and content of this Agreement, the TME RESEARCH Data, and protocols,
the analytical algorithms and techniques used by TME RESEARCH and/or COMPANY. Confidential Information does not include information
which was known to the receiving party or was in the public domain before disclosure, which becomes part of the public domain after
disclosure by publication or other means except by a breach of this Agreement by the receiving party, was received from a third
party under no duty or obligation of confidentiality to the disclosing party, or was independently developed by the receiving party
without reference to the Confidential Information.

 

1.4          “Data
Specifications” means the method, format, structure, organization, and content of
the data that TME RESEARCH will provide to COMPANY as further specified in the applicable SOW and which Data Specifications may
be modified from time to time in accordance with this Agreement.

 

1.5          “COMPANY
Data” means data in the possession of COMPANY that was not provided by TME RESEARCH.
In the event that COMPANY obtains data from other sources and that data is part of the TME RESEARCH Data at the time that duplicate
data is obtained from another source by COMPANY, then the TME RESEARCH Data shall continue to be considered to be TME RESEARCH
Data.

 

1.6          “HIPAA”
means the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. §1302d
et seq., as amended by the Health Information Technology for Economic and Clinical Health Act, Title XIII of Division A and Title
IV of Division B of the American Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5, and implementing regulations promulgated
thereunder, including the Privacy Standards, 45 C.F.R. Parts 160 and 164, and the omnibus rule changes to the Privacy and Security
Rules, as may be amended from time to time.

 

1.7           “Intellectual
Property” means all: (i) copyrights (including, without limitation, the right to
reproduce, distribute copies of, display and perform the copyrighted work and to prepare derivative works), copyright registrations
and applications, trademark (“TM”) rights, trademark registrations and applications, patent rights, patent applications
and patent issuances, trade names, mask-work rights, Trade Secrets, moral rights, author’s rights, privacy rights, publicity
rights, algorithms, rights in packaging, goodwill and other proprietary rights and all renewals and extensions thereof; (ii) intangible
legal rights or interests evidenced by or embodied in any idea, design, concept, technique, invention, discovery, enhancement or
improvement, whether or not patentable, copyrightable or trademarkable; and (iii) all derivatives of any of the foregoing.

 

2.           SERVICES

 

2.1          TME
RESEARCH will provide to COMPANY the services set forth in Exhibit A, a Statement of Work (“SOW”), which sets out with
specificity the services and deliverables to be provided and the fees to be paid. Additional SOWs may be executed by the parties
and will be incorporated into and governed by this Agreement for any other projects agreed to by the parties that will be governed
under this Agreement. If any term in a SOW conflicts with this Agreement, the SOW will control. All tissue samples provided to
COMPANY under this Agreement or any SOW shall become and remain the exclusive and sole property of the COMPANY; however, use of
such tissue samples shall remain as restricted in the related SOW under which they are provided.

 

2.2          Either
party may request changes to any services or deliverables set forth in an SOW by submitting a written request detailing the proposed
changes to the other party. The parties agree to negotiate and execute an amendment reflecting agreed-upon changes and any related
terms.

 

3.           LICENSE
GRANT

 

Subject
to the terms and conditions of this Agreement, TME RESEARCH hereby grants COMPANY a limited, non-exclusive, nontransferable, except
as provided herein, right and license to the TME RESEARCH Data and tissue samples for use exclusively as set forth within any SOW
under this Agreement. Nothing herein shall restrict TME RESEARCH from using TME RESEARCH Data for any and all purposes anywhere
in the world.

 

	Page 2 of 8	Confidential
	TME Research July 2014 Vers.02cf	 

 

    	 

    	 

    

 

4.           PAYMENTS

 

4.1          COMPANY
will pay to TME RESEARCH the fees specified in the applicable SOW. TME RESEARCH shall deliver all deliverables under an SOW provided
that COMPANY has fulfilled all of its payment obligations to date and subject to IRB approval(s). All invoiced amounts for services
performed in accordance with the terms and conditions of this Agreement and any SOW are due net thirty (30) days from the date
of invoice. If COMPANY identifies items in an invoice which are disputed, COMPANY will notify TME RESEARCH in writing, noting its
objection to the disputed item(s) with specificity, within ten (10) working days of the date of the invoice.

 

4.2          In
addition to all of the payments otherwise required under this Agreement, exclusive of any taxes imposed upon TME RESEARCH’
net income, COMPANY shall pay any and all taxes, duties, or excises imposed upon any payments made to TME RESEARCH hereunder by
any governmental authority, including without limitation any sales, use, service, value-added, withholding or similar taxes.

 

5.           TERM
AND TERMINATION

 

5.1          This
Agreement will commence on the Effective Date and will terminate on the third (3rd) anniversary of the Effective Date unless earlier
terminated in accordance with this Agreement, or unless extended by a written amendment and signed by both parties. Any SOW, the
duration of which extends beyond the expiration or termination of this Agreement, will continue to be performed for the term of
such SOW, and will continue to be governed by the terms of this Agreement, which terms shall remain in effect beyond the expiration
or termination of this Agreement solely with respect to such SOW, unless such SOW is also terminated in accordance with the terms
and conditions of this Agreement.

 

5.2          Either
party may immediately terminate this Agreement or any individual Statement(s) of Work, or TME RESEARCH may suspend performance
of Services, for a material breach of this Agreement or the applicable Statement(s) of Work by the other party (the “Breaching
Party”), provided that the Breaching Party fails to cure such material breach within forty-five (45) days (or thirty
(30) days for payment breaches) after receipt of written notice specifying such material breach.

 

5.3          Either
party may immediately terminate this Agreement or any SOW upon written notice to the other party upon the happening of any of the
following events: (i) if any certificate, authorization, approval or exemption from a regulatory authority required for the conduct
of the services is revoked, suspended, or expires without renewal; (ii) if the continuation of the services would be rendered illegal
or in violation of Applicable Law; or (iii) upon the other party’s becoming insolvent or unable to pay all material debts
when due, including without limitation if the other party files a petition in bankruptcy, or enters into an agreement with its
creditors, or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors,
or suffers or permits the entry of any order adjudicating it to be bankrupt or insolvent, prompt Notice of such event to be provided
to the other party to the extent permissible under any Applicable Law.

 

5.4          Either
party may terminate this Agreement or any SOW without cause upon sixty (60) days prior written notice to the other party, or as
may be otherwise provided in a SOW.

 

5.5          Upon
receipt of notice of termination of this Agreement or any Statement(s) of Work by either party: (i) the parties will, as soon as
reasonably practicable and in accordance with Applicable Laws, discontinue providing the applicable services, and no payments from
COMPANY to TME RESEARCH will be refundable unless otherwise defined in a SOW.

 

5.6          Termination
of this Agreement or of a SOW for any reason shall not affect the rights of the parties that have accrued on or before termination.

 

	Page 3 of 8	Confidential
	TME Research July 2014 Vers.02cf	 

 

    	 

    	 

    

 

6.    
      CONFIDENTIALITY AND PRIVACY COMPLIANCE

 

6.1         In
the event the receiving party (i) is required by Applicable Law to disclose the disclosing party’s Confidential Information,
or (ii) receives a subpoena, other validly issued administrative or judicial order, or a request pursuant to regulatory audit,
requesting Confidential Information of the disclosing party, then in any such case the receiving party may, to the limited extent
necessary to comply with the requirements of 6. l(i) or (ii), disclose the other party’s Confidential Information. In such
event, to the extent practicable and permitted by Applicable Law or the requesting government agency, the receiving party shall
promptly notify the disclosing party in writing of such request and provide reasonable assistance to the disclosing party, at the
disclosing party’s expense, if the disclosing party wishes to seek a protective order or similar relief.

 

6.2         Each
party may use the other party’s Confidential Information only in connection with its rights and obligations under this Agreement.
Except as expressly permitted herein, each party will maintain in confidence and will not disclose the other party’s Confidential
Information, using the same degree of care, but no less than reasonable care, as it uses to protect its own confidential information
of a similar nature. The receiving party may disclose the disclosing party’s Confidential Information only to the receiving
party’s respective employees, independent contractors, outside consultants (including its legal counsel, its insurance carriers
and agents, and its financial and accounting advisers) and actual and potential investors, lenders, acquirers and collaborators
who (i) have a need to know such Confidential Information; (ii) are made aware of the Confidential Information’s confidential
or proprietary nature; and (iii) are under a written obligation to protect confidential or proprietary information (including the
Confidential Information) no less restrictive than the obligations set forth herein. To the extent necessary to discharge a party’s
obligations under this Agreement, that party may disclose the other party’s Confidential Information to regulatory authorities,
ethics committees, and institutional review boards. To the extent that Confidential Information contains the disclosing party’s
standard operating procedures, confidential product specifications, proprietary data, trade secrets, or proprietary methods, no
portion thereof may be photocopied or replicated in any way.

 

6.3         TME
RESEARCH and COMPANY will comply with all Applicable Law relating to protection of personal information contained in the TME RESEARCH
Data and COMPANY databases, respectively. Notwithstanding anything to the contrary herein, all individually identifiable information
shall only be used and disclosed in accordance with HIPAA and Applicable Law. Any TME RESEARCH Data provided by TME RESEARCH to
COMPANY will be provided in accordance with the Data Specifications as set forth in the applicable SOW, and any COMPANY Data and/or
TME RESEARCH Data provided to a third party as intended under this Agreement or any SOW will be provided in accordance to HIPAA,
specifically in a manner consistent with 45 C.F.R. Section 164.514(b). Should COMPANY discover any TME RESEARCH Data that it reasonably
should know should be de-identified as described above which is not de-identified, COMPANY will use its best efforts to promptly
notify TME RESEARCH of such occurrence.

 

6.4         Disposal
of Confidential Information. Each Party agrees that, upon the disclosing party’s written request, the receiving party will
return to the disclosing party or destroy, as reasonably directed by the disclosing party. The foregoing notwithstanding, each
receiving party may retain one (1) archival copy of the disclosing party’s Confidential Information in a limited access file
for purposes of monitoring its ongoing obligations hereunder and to comply with any applicable regulatory requirements.

 

6.5         No
License Granted. Except as provided herein or specifically in a SOW hereunder, disclosure of Confidential Information under this
Agreement shall not be construed to create in or grant to the receiving party any license, right, title, interest, or ownership
in or to any of the disclosing party’s Confidential Information.

 

	Page 4 of 8	Confidential
	TME Research July 2014 Vers.02cf	 

 

    	 

    	 

    

 

6.6          Injunctive
Relief. Each party agrees that a breach of this Agreement by the receiving party may result in irreparable harm to the
disclosing party for which money damages would be inadequate. Consequently, in the event of a breach or threatened breach by
the receiving party of this Agreement, the disclosing party shall be entitled, without the requirement of posting a bond or
other security, to seek equitable relief, including injunctive relief and specific performance in addition to other remedies
available to the disclosing party at law or in equity.

 

7.     
     OWNERSHIP

 

7.1         No
right or license, or assignment of either party's patent, copyright, trademark, trade secret is granted under this Agreement.

 

7.2         As
between the parties, each party will retain full and exclusive ownership of all right, title, and interest in and to all of its
Intellectual Property, including materials, documents, Data, methodologies, systems and inventions provided by either party to
the other hereunder, except to the extent stated otherwise herein this Section 7.

 

7.3         Any
and all materials, documents, data, methodologies, systems, inventions, discoveries, derivatives, enhancements and improvements
that are deliverables or developed under a SOW, whether or not patentable, which are conceived, and prepared and/or developed,
by TME RESEARCH in the course of performing the services shall be the sole and exclusive property of TME RESEARCH, except
to the extent any COMPANY Intellectual Property is contained therein and except to the extent any reports or data analysis are
developed or derived from the services provided to COMPANY by TME RESEARCH under the terms of this Agreement which are deliverables
under this Agreement, in which case such derivative or newly developed data deliverables shall be owned by each party without
the need to account to the other party. Either party shall have the right to use such derivative or newly developed data deliverables
for its own business purposes without the need for authorization or consent from the other party.

 

7.4         Any
and all materials, documents, data, methodologies, systems, inventions, discoveries, derivatives, enhancements and improvements
that are deliverables or developed under a SOW, whether or not patentable, which are conceived, and prepared and/or developed,
by COMPANY shall be the sole and exclusive property of COMPANY (“COMPANY DERIVED IP”), except
to the extent any TME RESEARCH Intellectual Property is contained therein and except to the extent developed or derived by TME
RESEARCH and provided to COMPANY under the terms of this Agreement, or to the extent Data is provided as a Deliverable to TME Research
by COMPANY under the terms of this Agreement, in which case such derivative or newly developed data shall be owned by each party
without the need to account to the other party. Either party shall have the right to use such derivative or newly developed data
for its own business purposes without the need for authorization from the other party. For clarity, notwithstanding
anything in this Agreement or SOW to the contrary, the parties agree that COMPANY DERIVED IP, shall at all times remain the sole
and exclusive property of the COMPANY and shall include all materials, documents, data, methodologies, systems, inventions, discoveries,
derivatives, enhancements and improvements, whether or not patentable, that are derived from the NextCYTE micro array test, including
any such derivations using the TME RESEARCH Intellectual Property that is licensed or otherwise provided to COMPANY under this
Agreement or any SOW. By way of example and without limitation, if a SOW requires that COMPANY provide any data, test, results
or analysis of the NextCYTE micor array tests to TME then such data, test, result or analysis shall remain the sole and exclusive
property of COMPANY.

 

7.5         For
purposes of clarity, such business purposes mentioned in Sections 7.3 and 7.4 above shall include, but shall not be limited to,
the right of publication under its own name and in accordance with Section 10. Notwithstanding anything to the contrary contained
herein, the parties agree that if the other party’s name or products or reference to the project that is the subject of any
particular SOW is made in writing, the other party shall have the right to review and comment on any such publication prior to
release of such publication.

 

	Page 5 of 8	Confidential
	TME Research July 2014 Vers.02cf	 

 

    	 

    	 

    

 

8.      
    LIMITATION OF LIABILITY AND INDEMNIFICATION

 

8.1         EXCEPT
AS PROVIDED BELOW, NEITHER PARTY OR ANY THIRD PARTY LICENSOR OF A PARTY SHALL BE LIABLE FOR ANY SPECIAL, CONSEQUENTIAL, PUNITIVE,
INCIDENTAL, OR INDIRECT DAMAGES, OR ANY DAMAGES FOR LOST DATA, BUSINESS INTERRUPTION, LOST PROFITS, LOST REVENUE, OR LOST BUSINESS,
ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, HOWEVER CAUSED AND BASED ON ANY THEORY OF LIABILITY, ARISING OUT OF THIS AGREEMENT,
WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE
OF ANY LIMITED REMEDY. IN NO EVENT WILL THE AGGREGATE LIABILITY OF ANY PARTY UNDER THIS AGREEMENT EXCEED THE TOTAL FEES PAID UNDER
THIS AGREEMENT OR THE APPLICABLE SOW DURING THE TWELVE MONTHS IMMEDIATELY PRECEDING THE EVENT GIVING RISE TO THE CAUSE OF ACTION.

 

8.2         Indemnification.
Subject to Section 8.1 above, including without
limitation the aggregate liability of each Party, each Party (the “Indemnifying Party”) shall indemnify
and hold harmless the other Party, and their respective directors, employees, consultants and agents (the “Indemnified Parties”)
from and against any and all liabilities, losses, damages, costs, and other expenses (including reasonable attorneys’ fees)
(“Losses”) incurred by the Indemnified Parties as a result of any claim, demand, action or proceeding by any third
party against such Indemnified Parties (each, a “Claim”) to the extent arising from or relating to any material breach
of any representation, warranty, covenant, or obligation of the Indemnifying Party under this Agreement, or any gross negligence
or willful misconduct by the Indemnifying Party or any of its employees, agents, or subcontractors, provided the Indemnifying Party
is found liable for such expenses as adjudicated in a final court of competent jurisdiction, if the Indemnifying Party so chooses
to go to a court of last resort, otherwise the initial court of competent jurisdiction.

 

8.3         Settlement.
No settlement or compromise of a Claim subject to the indemnification provision will be binding on either Party without prior written
consent. Such consent of settlement or compromise will not be unreasonably withheld, conditioned or delayed. Neither party will
admit fault on behalf of the other Party without the prior written approval of that party.

 

9.  
        WARRANTIES AND DISCLAIMER

 

9.1          Each
Party represents and warrants to the other that: (i) it has the full corporate or limited liability power, as applicable, to enter
into this Agreement and to perform its obligations hereunder; (ii) this Agreement constitutes a legal, valid and binding obligation
of such Party, enforceable against such Party in accordance with its terms; and (iii) this Agreement does not contravene, violate
or conflict with any other agreement of such Party.

 

9.2          EXCEPT
AS OTHERWISE SET FORTH IN THIS AGREEMENT, ALL MATERIALS, PRODUCTS AND SERVICES, IF ANY, ARE PROVIDED “AS IS,” “WHERE
IS” AND WITHOUT WARRANTY OF ANY KIND. EXCEPT AS SPECIFICALLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES, AND EACH PARTY
EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES IN CONNECTION WITH ANY AND ALL MATERIALS, PRODUCTS AND SERVICES PROVIDED
PURSUANT TO THIS AGREEMENT, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS, TITLE, ANY WARRANTIES ARISING OUT OF A COURSE OF PERFORMANCE,
DEALING OR TRADE USAGE, AND THEIR EQUIVALENTS UNDER THE LAWS OF ANY JURISDICTION.

 

	Page 6 of 8	Confidential
	TME Research July 2014 Vers.02cf	 

 

    	 

    	 

    

 

10.         PUBLICITY

 

Except as
necessary to perform the services and except as limited below in this Section, the parties agree they shall not disclose the existence
or the terms and conditions of this Agreement or any associated Statements of Work to any thirdparty, except asmay berequired
(i) toimplement or enforce the terms of this Agreement; (ii) by legal procedure or bylaw; or (iii) byan existing or
potential investor, acquiring company, bank or other financial institution, under appropriate non-disclosure terms in connection
with a merger, acquisition, financing, loan agreement or similar corporate transaction; and the parties agree they shall not, except
as required by legal procedure or by law, without first obtaining the prior written consent of the other party, (i) announce this
Agreement in a press release or promotional material, (ii) disclose TME RESEARCH as the source of any data provided to COMPANY
to any third party without the written consent of TME RESEARCH; or (iii) use each other’s name, symbols or marks in any form
of publicity without the prior written consent of the other party.

 

11.         INDEPENDENT
CONTRACTOR

 

The relationship
of the parties to each other under this Agreement is that of independent contractors, and nothing contained herein will be construed
to constitute, create, or in any way be interpreted as, a joint venture, partnership, or business organization of any kind. Except
as expressly provided for in this Agreement, under no circumstances will the employees or agents of one party be considered employees
or agents of the other party. Neither party may act in a manner which expresses or implies a relationship other than that of independent
contractor, nor bind the other party.

 

12.         ASSIGNMENT

 

Either party
may assign this Agreement without the other party’s prior written consent to a successor in interest by reason of merger,
acquisition, partnership, license agreement or otherwise; provided that no assignment to a direct competitor of the other party
will be permitted without such other party’s prior written consent. Except as expressly provided in this Section, neither
party will have the right to assign this Agreement or any of its rights or obligations hereunder without the prior written consent
of the other party, which consent will not be unreasonably withheld, conditioned or delayed. Any attempt at assignment in violationof
this Section shall be null and void.

 

13.         DISPUTE
RESOLUTION

 

If a dispute
arises between the parties relating to this Agreement, the parties will meet and attempt to resolve the dispute in good faith.
In the event the dispute is not resolved through negotiation within ten business days after said meeting, the parties will submit
to confidential, non-binding mediation before a mutually acceptable mediator. Each party will designate at least one corporate
officer with full authority to resolve the dispute who will attend and participate in the mediation. If the dispute remains unresolved
after mediation, then each party will be free to pursue any available remedy at law or in equity. Each party will bear its own
legal fees and any costs incurred under this Section.

 

14.         GENERAL

 

14.1        Notice.
Any notice or communication required or permitted hereunder shall be in writing and shall
be deemed received (i) on the date received if delivered by a reputable overnight delivery service, or (ii) three days after the
date postmarked if sent by first class, registered or certified mail, with return receipt requested. Notice given under this Section
15.1 shall be sent to the parties at the addresses first cited above (or such other address as the applicable party may provide
by written notice):

 

	Page 7 of 8	Confidential
	TME Research July 2014 Vers.02cf	 

 

    	 

    	 

    

 

14.2       Insurance.
Each party will maintain in full force and effect throughout the performance of this Agreement
worker’s compensation, general liability, automobile liability, and professional general or product liability insurance coverage
in amounts appropriate to conduct its business and sufficient to cover its indemnification obligations hereunder, at its sole cost
and expense.

 

14.3       Severability.
If any term of this Agreement is declared unenforceable, then the unenforceability thereof
will not affect the remaining terms of this Agreement, provided the commercial goals of the Agreement or relevant SOW may be reasonably
met.

 

14.4       Waiver.
Failure to enforce any of the terms or conditions of this Agreement will not constitute
a waiver of any such terms or conditions, then or in the future, or of any other terms or conditions.

 

14.5       Governing
Law and Forum; Compliance with Law. This Agreement will be governed by and construed in
accordance with the laws of the State of Pennsylvania, without regard to its conflict of laws provisions. The parties hereby consent
to the exclusive jurisdiction of the state and federal courts located in the State of Pennsylvania.

 

14.6       Compliance
with Law. Each party is responsible for compliance with all Applicable Laws pertaining
to the performance of its obligations under this Agreement, including without limitation HIPAA or any other applicable law relating
to security or privacy of information or the exchange of health information.

 

14.7        Entire
Agreement. This Agreement, including any Statement(s) of Work, amendments and attachments
hereto, constitutes the entire understanding of the parties hereto with respect to the subject matter hereof and supersedes and
replaces all prior contracts, agreements, and understandings relating to the same subject matter, whether written or oral. No waiver,
consent, change or modification to this Agreement will be binding, unless in writing and signed by duly authorized representatives
of TME RESEARCH and COMPANY. The Attachments and any amendments attached hereto and referenced herein shall constitute an integral
part of this Agreement. Section titles and headings contained in this Agreement are intended for convenience only and are not intended
to effect the interpretation or construction of any term or provision hereof. This Agreement may be executed in counterparts. Those
provisions of this Agreement which, by their nature are meant to survive any termination of this Agreement will so survive.

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement through their duly authorized representatives as of
the Effective Date.

 

	TME Research	 	The National Reference Laboratory for 

Breast Health, Inc.
	 	 	 	 	 
	By:	/s/ Mark Gittleman	 	By:	/s/ Kyle Guse
	Name:	Mark Gittleman	 	Name: 	Kyle Guse
	Title:	President	 	Title:	CFO
	Date:	9/1/14	 	Date:	9/15/14

 

	Page 8 of 8	Confidential
	TME Research July 2014 Vers.02cf	 

 

    	 

    	 

    

 

 

EXHIBIT A

Statement of Work

 

TME Research,
LLC

and

The National Reference
Laboratory for Breast Health, Inc.

 

Project: NextCyte
Full Transcriptome Data Analysis of Patients with Invasive Breast Cancer

 

Terms and Conditions

 

This Statement
of Work, effective as of September 1, 2014, (the "Effective Date of the Statement of Work"), is entered into pursuant
to and under the terms and conditions of the TME Research Master Services Agreement between TME Research and The National Reference
Laboratory for Breast Health, Inc. effective as of August 29, 2014. The terms of the TME Research Master Services Agreement ("Master
Agreement") and the terms of this Statement of Work shall apply to this project. Should there be any inconsistencies between
the terms, the terms of this Statement of Work shall take precedence.

 

Overall Obiectives/Scope
of Work

 

In
accordance with the terms and conditions in the Master Agreement and the terms of this SOW and any of its Exhibits or
other agreed to documents duly signed by representatives of the parties, the major objectives
are as defined below:

 

Objective:
To provide matched sets of de—identified tissue samples and clinically annotated retrospective data on 100 breast
cancer patients for testing and evaluation of the NextCyte gene test

 

Tasks include:

 

		·	TME will provide to NRLBH tissue sample slides from formalin fixed
paraffin embedded (FFPE) blocks and matched de—identified clinically annotated data (de—identified in accordance with
HIPAA regulations) such as patient age, tumor characteristics, nodal status, staging, recurrence and death, as defined by NRLBH
requirements and agreed to in writing by both parties

		·	NRLBH to use its NextCyte gene chip microarray test on the tissue
samples provided by TME and provide per sample results back to TME

		·	NRLBH shall perform own data analysis
and provide the results of such testing and analysis to TME

		·	TME will provide Consultant Services, at the rates stated below, including
interpretation of these data clinical value, and recommendations for next steps, if desired by NRLBH

  

	SOW for NextCyte Full Transcriptome Analysis of Patients for TME Research	 	CONFIDENTIAL

 

    	 	 	 

    	 

    

  

If mutually
desirable and agreed upon by NRLBH and TME for the fees outlined below for Consulting Services, TME principle investigators may
co—author publication/s of the results

 

TME Tissue Samples with
Clinical Annotations will be provided per the description below:

		·	100 FFPE de—identified (no patient
identifiers) breast tissue samples with clinically relevant annotations specific to the
NRLBH testing objective/s for NextCyte gene chip microarray test to include:

o   50
from patients diagnosed with node positive disease with five year minimum follow up

o   50
from patients diagnosed with node negative disease with five year minimum follow up

o   Samples
from up to 4 diverse breast specialist practices

Clinical annotations
will include traditional pathologic parameters and the 5year + follow up data, such parameters as requested by NRLBH and agreed
to in writing by TME.

 

Tissue Sample/Data Use

 

All of the
data/samples/reports provided by TME to NRLBH, as documented within this SOW, will be used for the sole purpose of establishing
that NextCyte gene chip microarray test alone and/or in conjunction with the clinical and pathology report results can analyze
breast cancer from FFPE tissues samples in a retrospective cohort and predict:

 

1)
Lymph node status

2)
Five year recurrence

3)
Systemic treatment impact

 

The
tissue samples, or any parts thereof, and/or annotated clinical data provided by TME shall not be used for any other purpose(s)
unless agreed to in writing by TME prior to such use(s). The parties agree that the tissue samples or any data provided by TME
to NRLBH will not be used for subject identification. The parties agree that certain other uses may require a separate agreement,
including separate costs, for such usage, that is agreed upon by the parties.

 

Deliverables and Timelines

 

	Deliverable	 	Timeline
	 	 	 
	TME provide a total of 100 patient tissue samples plus matched clinical data	 	As soon as practically feasible after Master Agreement and SOW signing and upon receipt of clinical data requirements from NRLBH
	 	 	 
	TME provide additional tissue samples plus clinical data to complete the project (as needed and determined by NRLBH)	 	As soon as practically feasible after receipt of request
	 	 	 
	NRLBH to provide sample test results to TME	 	Upon completion of testing
	 	 	 
	NRLBH provide to TME analysis and review of aggregate and analyzed data	 	TBD
	 	 	 
	TME provide Consulting services	 	TBD

  

	SOW for NextCyte Full Transcriptome Analysis for TME Research	   2	CONFIDENTIAL

 

    	 	 	 

    	 

    

 

Compensation

 

Based
on the scope of the project outlined in this Statement of Work, the total cost of this project will be $162,600, plus any additional
fees for Consulting Services billed at the hourly Consultant rate provided herein.

 

Payment
Schedule

 

The
parties agree to the payment amounts and due dates for such payments as provided below. Payments shall be made by NRLBH by check
to TME:

 

TME
Research

Suite
302

250
Cetronia Road

Allentown,
Pa. 18104

 

	Description of Services Provided	 	Due Date	 	Amount
	 	 	 	 	 
	
        Start—Up
        Costs:

        ·
        Study Concept development including review of data requirements and objectives, create data
        collection strategy, development of research protocol and clinically annotated data collection tool and IRB submission for PI and
        Sub—investigators

        ·
        Licensing of/Access to/utilization of TME database for study purposes

        ·
        Investigator site start up and training costs

        ·
        PI site admin/closing costs/document storage, etc.

        ·
        Investigator path lab start up and training costs
	 	At Master Agreement and SOW Signing, receipt of data requirements from NRLBH	 	$99,600
	 	 	 	 	 
	
        Slide
        Preparation & Delivery — Initial Delivery:

        ·
        Study Supervision—Clinical Coordinator/project manager

        ·
        Screening and enrollment of patients for inclusion

        ·
        Pathology slide prep, shipping

        ·
        Data extraction and organization from TME database
	 	At time of Initial Delivery of first 25 samples plus data sets	 	$31,500

  

	SOW for NextCyte Full Transcriptome Analysis for TME Research	   3	CONFIDENTIAL

  

    	 	 	 

    	 

    

  

	
        Slide
        Preparation & Delivery — Final Delivery & Payment for any Additional Slide Delivery:

        · Study
        Supervision—Clinical Coordinator/project manager

        ·
        Screening and enrollment of patients for inclusion

        ·
        Pathology slide prep, shipping,

        ·
        Data extraction and delivery from TME database
	 	At time of final Delivery	 	$31,500
	 	 	 	 	 
	Additional
    patient screening, data extraction, preparation slide and shipping to meet stated objective of 100 evaluable patients	 	Upon Delivery	 	$450 per slide set with annotated data (slide set defined as set of FFPE slides provided for each patient)
	
        Consulting
        Services:

        •
        Analysis

        •
        Interpretation/recommendations

        •
        Publications
	 	TBD (as agreed to in writing by the parties)	 	$500/hour/consultant

 

Additional Terms

 

In
addition to the terms and conditions of the Master Agreement, the parties agree:

		(1)	that TME shall have the right to audit the processes/procedures used by NRLBH to conduct the testing
and to audit the results of the tests reported by NRLBH. Such audit(s) will be conducted at a reasonable time and place agreed
to by the parties after such request for audit is made by TME. All TME costs associated with such audit shall be borne by TME;
and

 

Administrative Detail

 

		·	All state and federal laws regarding privacy,
including HIPAA, will be followed in this engagement.

		·	This Statement of Work is consistent with meeting the protections
stipulated by the Department of Health and Human Services' regulations related to the payment for personal and/or management services
set forth at 42 C.F.R. §1001.952(d). No health care providers will receive any payments, or other remuneration, for the purpose
of inducing them to utilize any TME product or service.

		·	TME represents and warrants that the fees
charged to NRLBH are standard and are at or below the rates charged to other TME customers for the same or similar services. These
rates are Fair Market Value (FMV) for the expertise offered by TME.

  

	SOW for NextCyte Full Transcriptome Analysis for TME Research	   4	CONFIDENTIAL

 

    	 	 	 

    	 

    

 

IN WITNESS WHEREOF, the parties have accepted and agreed to this Statement of Work:

  

	TME Research, LLC	 	The National Reference Laboratory for Breast Health, Inc.
	 	 	 	 	 
	By:	/s/ Mark Gittleman	 	By:	/s/ Kyle Guse
	Name: 	Mark Gittleman	 	Name:	Kyle Guse
	Title: 	President	 	Title:	CFO
	Date: 	9/1/14	 	Date:	9/14/14

 

	SOW for NextCyte Full Transcriptome Analysis for TME Research	   5	CONFIDENTIALExhibit 4.1

 

[Form of Note]

 

THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITORY OR A NOMINEE THEREOF. THIS SECURITY MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A SECURITY REGISTERED, AND NO TRANSFER OF THIS SECURITY IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY PERSON OTHER THAN SUCH DEPOSITORY OR A NOMINEE THEREOF, EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE.

 

KINROSS GOLD CORPORATION

 

5.95% Senior Notes due 2024

 

CUSIP No. [·]

 

	
No. [·]
    	
$[·]
    

 

Kinross Gold Corporation, a corporation duly organized and existing under the laws of the Province of Ontario, Canada (herein called the “Company”, which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co., or registered assigns, the principal sum of [·], on March 15, 2024, and to pay interest and Additional Amounts (if any) thereon from the most recent Interest Payment Date to which interest has been paid or duly provided for, semi-annually on March 15 and September 15 in each year, at the rate of 5.95% per annum (computed on the basis of a 360-day year consisting of twelve 30-day months), until the principal hereof is paid or made available for payment. The interest and Additional Amounts (if any) so payable, and punctually paid or duly provided for, on any Interest Payment Date shall, as provided in such Indenture, be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on the Regular Record Date for such interest, which shall be the March 1 or September 1 (whether or not a Business Day), as the case may be, next preceding such Interest Payment Date. Any such interest and Additional Amounts (if any) not so punctually paid or duly provided for shall forthwith cease to be payable to the Holder on such Regular Record Date and may either be paid to the Person in whose name this Security (or one or more Predecessor Securities) is registered at the close of business on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed, and upon such notice as may be required by such exchange, all as more fully provided in said Indenture.

 

Payment of the principal of (and premium, if any) and any such interest on, and any Additional Amounts with respect to, this Security shall be made at the office or agency of the Company maintained for that purpose in The Borough of Manhattan in the City of New York, in such coin or currency of the United States of as at the time of payment is legal tender for payment of public and private debts; provided, however, that at the option of the Company payment of interest and Additional Amounts (if any) may be made by check mailed to the address of the Person entitled thereto as such address shall appear in the Security Register.

 

 

Reference is hereby made to the further provisions of this Security set forth on the reverse hereof, which further provisions shall for all purposes have the same effect as if set forth at this place.

 

Unless the certificate of authentication hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose.

 

 

IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed under its corporate seal.

 

 

	
 
    	
KINROSS   GOLD CORPORATION
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By
    	
 
    

 

 

This is one of the Securities of the series designated therein referred to in the within-mentioned Indenture.

 

Dated:

 

	
 
    	
WELLS   FARGO BANK, NATIONAL ASSOCIATION
    
	
 
    	
As   Trustee
    
	
 
    	
 
    
	
 
    	
By
    	
 
    
	
 
    	
Authorized   Signatory
    

 

 

Reverse of Security

 

This Security is one of a duly authorized issue of securities of the Company (herein called the “Securities”), issued and to be issued in one or more series under an Indenture, dated as of August 22, 2011, as amended, supplemented or otherwise modified (herein called the “Indenture”, which term shall have the meaning assigned to it in such instrument), among the Company, the Guarantors party thereto and Wells Fargo Bank, National Association, as Trustee (herein called the “Trustee”, which term includes any successor trustee under the Indenture), and reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and delivered. This Security is one of the series designated on the face hereof.

 

The Securities of this series are subject to redemption upon not less than 30 days’ (but not more than 60 days’) prior notice, as a whole or in part, at any time prior to December 15, 2023, at the election of the Company, at a Redemption Price (expressed as a percentage of the principal amount) equal to the greater of (i) 100% of the principal amount of the Notes called for redemption and (ii) the sum of the present values of the remaining scheduled payments of principal and interest on such Notes (exclusive of interest accrued to the date of redemption) discounted to the redemption date on a semi-annual basis (assuming a 360-day calendar year consisting of twelve 30-day months) at the Treasury Rate plus 50 basis points, as calculated by the Independent Investment Banker upon whom the Company, the Trustee and any paying agent shall be entitled to rely conclusively for such purposes, plus, in each case, accrued interest thereon to, but not including, the date of redemption, but interest installments whose Stated Maturity is on or prior to such Redemption Date will be payable to the Holders of such Securities, or one or more Predecessor Securities, of record at the close of business on the relevant Record Dates referred to on the face hereof, all as provided in the Indenture. On or after December 15, 2023, the Notes may be redeemed in whole, but not in part, at a redemption price equal 100% of the principal amount of the Notes plus accrued interest thereon to, but not including, the date of redemption.

 

The provisions of the Indenture requiring the Company to make a repurchase offer, if a Change of Control Repurchase Event occurs, apply to this Security.

 

The Indenture contains provisions granting the Company the right to redeem this Security at any time if certain adverse changes occur with respect to the tax treatment of this Security.

 

In the event of redemption of this Security in part only, a new Security or Securities of this series and of like tenor for the unredeemed portion hereof will be issued in the name of the Holder hereof upon the cancellation hereof.

 

The Indenture contains provisions for defeasance at any time of the entire indebtedness of this Security or certain restrictive covenants and Events of Default with respect to this Security, in each case upon compliance with certain conditions set forth in the Indenture.

 

If an Event of Default with respect to Securities of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in the manner and with the effect provided in the Indenture.

 

The Indenture contains provisions requiring the Company to pay certain Additional Amounts in respect of this Security in the event it is required to withhold certain Taxes by certain governmental authorities.

 

 

The Indenture contains a Negative Pledge on the part of the Company, which applies to this Security.

 

The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with the consent of the Holders of a majority in principal amount of the Securities at the time Outstanding of each series to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the Securities at the time Outstanding, on behalf of the Holders of all Securities, to waive compliance by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof, whether or not notation of such consent or waiver is made upon this Security.

 

As provided in and subject to the provisions of the Indenture, the Holder of this Security shall not have the right to institute any proceeding with respect to the Indenture or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given the Trustee written notice of a continuing Event of Default with respect to the Securities of this series, the Holders of not less than 25% in principal amount of the Securities with respect to which an Event of Default has occurred at the time Outstanding shall have made written request to the Trustee to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee indemnity satisfactory to it, and the Trustee shall not have received from the Holders of a majority in principal amount of Securities with respect to which an Event of Default has occurred at the time Outstanding a direction inconsistent with such request, and shall have failed to institute any such proceeding, for 60 days after receipt of such notice, request and offer of indemnity. The foregoing shall not apply to any suit instituted by the Holder of this Security for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective due dates expressed herein.

 

No reference herein to the Indenture and no provision of this Security or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of and any premium and interest on, and any Additional Amounts with respect to, this Security at the times, place and rate, and in the coin or currency, herein prescribed.

 

As provided in the Indenture and subject to certain limitations therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any premium interest on  and any Additional Amounts with respect to, this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees.

 

The Securities of this series are issuable only in registered form without coupons in denominations of $2,000 and integral multiples of $1,000 in excess of $2,000. As provided in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate principal amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder surrendering the same.

 

 

No service charge shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith.

 

Prior to due presentment of this Security for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether or not this Security be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary.

 

All terms used in this Security which are defined in the Indenture shall have the meanings assigned to them in the Indenture.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]